Long-term efficacy and safety of pembrolizumab in metastatic urothelial carcinoma
Dr. Peter O'Donnell
Immune checkpoint inhibitors are a standard therapy in metastatic urothelial carcinoma (mUC). Long-term follow-up is necessary to confirm durability of response and identify further safety concerns. Approximately five year follow-up analysis of the KEYNOTE-045 and KEYNOTE-052 trials found that pembrolizumab monotherapy continued to demonstrate durable efficacy with no new safety signals in patients with platinum-resistant mUC and as first-line therapy in cisplatin-ineligible patients.
